UroGen Pharma Ltd. (URGN)
Nasdaq: URGN · Pharmaceutical Preparations · Ra'Anana, IL · filing with the SEC since 2016
Who owns UroGen Pharma Ltd.
As filed with the SECHolders of 5% or more
3
Toronto Dominion Bank holds 6.7% of Ordinary Shares, par value NIS 0.01 per share, as its SCHEDULE 13G/A filed Aug 12, 2026 says.
Directors and officers
10
report now, of 19 people on the record since 2017. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Toronto Dominion Bank
SCHEDULE 13G/A · filed Aug 12, 2026 · Ordinary Shares, par value NIS 0.01 per share · 5.4% in May 15, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 5.2% in Apr 27, 2026
Morgan Stanley
SCHEDULE 13G · filed Aug 6, 2025 · Ordinary Shares · 1.8% in Feb 5, 2025
Menora Mivtachim Holdings Ltd
SCHEDULE 13G/A · filed Mar 17, 2025 · Ordinary Shares, par value NIS 0.01 per share · reported falling below 5%
Soleus Capital Master Fund, L.P.
SCHEDULE 13G/A · filed Aug 5, 2025 · Ordinary Shares, par value NIS 0.01 per share · reported falling below 5%, from 5% in Jun 16, 2025
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed May 15, 2026 · Ordinary Shares, par value NIS 0.01 per share · reported falling below 5%, from 9% in Nov 14, 2025
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed May 12, 2025 · Ordinary Shares, par value NIS 0.01 per share · reported falling below 5%, from 6.94% in Feb 12, 2025
Fred Cohen
SCHEDULE 13D/A · filed Jun 9, 2025 · Ordinary Shares, par value NIS 0.01 per share · reported falling below 5%
Cowen Financial Products LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Ordinary Shares, par value NIS 0.01 per share · reported falling below 5%, from 6.9% in Jul 29, 2025
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2025 · Ordinary Shares, par value NIS 0.01 per share · reported falling below 5%, from 7% in May 15, 2025
What URGN reports owning in othersstakes of 5% or more, and other ties
UroGen Pharma Ltd. reports no stake in another company in the record.
Insider tradesForm 4
15sales
0purchases
4sales on a scheduled plan
3people selling
$4.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 9, 2025 to Oct 9, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 9, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 23 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Schoenberg Mark | Chief Medical Officer | 10 | $4.5M | 4 | 0 | $0 |
| Smith Jason Drew | General Counsel | 4 | $200,000 | 0 | 0 | $0 |
| Degnan Chris | Chief Financial Officer | 1 | $100,000 | 0 | 0 | $0 |